Skip to content

Biohaven BHVN Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
uniQure logo
uniQureQURE
Roivant Sciences logo
Roivant SciencesROIV
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's deferred tax assets and other non-current assets?
Biohaven (BHVN) reported deferred tax assets and other non-current assets of $45.71M in Q1 2026.
How has Biohaven's deferred tax assets and other non-current assets changed year-over-year?
Biohaven's deferred tax assets and other non-current assets increased by 18.4% year-over-year, from $38.61M to $45.71M.
What is the long-term trend for Biohaven's deferred tax assets and other non-current assets?
Over 4 years (2021 to 2025), Biohaven's deferred tax assets and other non-current assets has grown at a 34.6% compound annual growth rate (CAGR), from $14.44M to $47.36M.